Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency
Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency
复制标题
DOI：
10.1111/j.1365-2141.2006.06379.x
复制
发表时间：
2007-01-01
影响因子：
6.5
通讯作者：
Watson, H. G.
中科院分区：
文献类型：
--
作者：
Baglin, T. P.;Cousins, D.;Watson, H. G.
英国血液学标准委员会(BCSH)于1998年发布了第三版口服抗凝指南(英国血液学标准委员会，1998年)，并于2006年进行了更新(Baglin等人，2006年)。这些关于安全指标的建议是对这些指导方针的补充。风险和建议伴随着开始口服抗凝治疗的患者和接受口服抗凝治疗的患者的安全指标清单。并不是每项服务都必须采用所有指标；而是提供了一种选择，从中选择那些被认为对当地情况和需要最有用的指标。预计将通过监测或审计，使用指标来制定服务发展和控制保证的标准(见治理部分)。在以前的指南中，“口服抗凝剂”一词指的是口服维生素K拮抗剂，如华法林。指南的初稿由编写小组编写，并根据多学科意见委员会、BCSH和英国血液学会(BSH)的意见以及适当时纳入的意见进行了修改。引用证据水平和等级的标准与英国疾病控制与预防中心委托制定的指南程序附录3中的标准相同(http://Nvww.bcshguidelines.com).The本指南的目标受众是参与口服抗凝治疗患者管理的医疗专业人员。
The British Committee for Standards in Haematology (BCSH) published its third edition of Guidelines on Oral Anticoagulation in 1998 (British Committee for Standards in Haematology, 1998) with an update in 2006 (Baglin et al, 2006). These recommendations on safety indicators compliment those guidelines. Risks and recommendations are accompanied by lists of safety indicators for patients starting oral anticoagulant therapy and for patients established on oral anticoagulant therapy. Not all indicators will necessarily be adopted by every service; rather a selection is provided from which to choose those considered most useful for local circumstances and needs. It is envisaged that indicators will be used to set standards for service development and for controls assurance, either by monitoring or audit (see section on Governance).As in the previous guidelines the term 'oral anticoagulant' refers to oral vitamin K antagonists (VKA), such as warfarin. Initial drafts of the guideline were produced by the writing group and modified in accordance with comments from a multidisciplinary sounding board, the BCSH and the British Society for Haematology (BSH) and comments incorporated where appropriate. Criteria used to quote levels and grades of evidence are as in appendix 3 of the Procedure for Guidelines Commissioned by the BCSH (http://Nvww.bcshguidelines.com).The target audience for this guideline is healthcare professionals involved in the management of patients receiving oral anticoagulant therapy.